Cefoperazone

Summary

Cefoperazone (CHEMBL507674) is an approved small-molecule antibacterial drug (ATC J01DD12); indicated across 2 conditions including bacterial infectious disease and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DD12
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 645.7 Da · C25H27N9O8S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL507674
Name	Cefoperazone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	44187
ChEBI	CHEBI:3493
ATC	J01DD12
Molecular formula	C25H27N9O8S2
Molecular weight	645.7
InChIKey	GCFBRXLSHGKWDP-XCGNWRKASA-N

SMILES: CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O

IUPAC name: (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Cefoperazona, Cefoperazone, Peracef, SID29215387, Cefoparazone, cefoperazone, CEFOPERAZONE

Parent form; salt/anhydrous children: CHEMBL1200482, CHEMBL1551899, CHEMBL1697715

Patent coverage: 6,747 distinct patent families (23,712 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Microtubule-associated protein tau, Fructose-bisphosphate aldolase, 4’-phosphopantetheinyl transferase ffp, Solute carrier family 22 member 6, Organic anion transporter 3, Solute carrier family 22 member 11, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 8 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC22A6	6.68	Ki	210	nM	CHEMBL_ACT_11002267
SLC22A8	5.72	Ki	1890	nM	CHEMBL_ACT_11002338
SLC22A11	5.55	Ki	2800	nM	CHEMBL_ACT_11002764
PDE3A	5.02	AC50	9500	nM	CHEMBL_ACT_25191140

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00360607	PHASE4	COMPLETED	A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections
NCT01992198	PHASE4	UNKNOWN	Multi-center Clinical Study of Early Antibios of Severe Acute Pancreatitis
NCT05654090	PHASE4	UNKNOWN	Evaluate Bioequivalence of Burotam (1/1 g/Vial)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).